SAN FRANCISCO, July 18 — When the chief executives of the world’s leading artificial intelligence companies all warn of risks from their own creations, it is worth paying attention. Sam Altman of OpenAI, Elon Musk of Tesla and SpaceX, and Demis Hassabis of DeepMind have each expressed concerns about where AI may be heading — even as their companies race to advance it.
The encouraging part is that these leaders are not dismissing the dangers. Altman, born in 1985 and now 41, was briefly fired by the OpenAI board on November 17, 2023, and reinstated just five days later after an employee backlash. That upheaval reflected deep internal debate about the direction of the technology. Musk, born 1971, signed the March 2023 open letter calling for a pause in advanced AI development. Hassabis, born 1976, has long advocated for responsible AI development as co-founder and CEO of DeepMind, which Google acquired in 2014.
A History of Breakthroughs and Warnings
DeepMind built AlphaGo, which beat world champion Lee Sedol in March 2016 — a moment many date as the modern dawn of public AI awareness. In 2020, DeepMind released AlphaFold, which solved a 50-year-old problem in protein folding, a breakthrough with major implications for drug discovery and health research. As a journalist who covers health and cancer news, I find that AlphaFold story particularly striking: the same underlying deep-learning techniques that AlphaGo used to master Go were adapted to predict how proteins fold, opening new avenues for understanding diseases.
But Hassabis has been a target of activist criticism as well. Altman’s OpenAI launched ChatGPT and GPT-4, bringing generative AI to hundreds of millions of users. Musk founded xAI in 2023 and maintains a visible security presence, having faced numerous personal threats.
All three have publicly expressed concerns about AI risks while leading its advancement. This is the paradox at the heart of the story: the people building the most powerful AI systems are among those most worried about what those systems could do.
What Patients Should Understand
From a health perspective, early findings suggest that AI tools trained on medical data can assist in diagnosis, drug discovery, and treatment planning. AlphaFold is already being used to model proteins linked to cancer, and researchers are exploring how large language models could help doctors interpret medical records or explain test results to patients.
But patients should be cautious. These models can make mistakes, and the evidence base for many AI medical tools is still thin. Talk to your doctor before acting on any AI-generated health advice. The technology is promising, but it is not yet a replacement for clinical judgment.
The encouraging part is that companies like DeepMind and OpenAI are investing heavily in safety research, even as they release products. Whether those investments are enough remains an open question. The history of technology suggests that the companies that move fastest do not always move most safely.
For now, the three chief executives continue to push forward — Altman at OpenAI, Musk at xAI, and Hassabis at DeepMind — each aware that the risks they warn about could one day be realised by their own creations. Patients, doctors, and policymakers will need to watch closely, ask hard questions, and consult their own experts.
Sources
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Tech Titans Altman, Musk, Hassabis Face AI Scrutiny”, “description”: “SAN FRANCISCO, July 18 — When the chief executives of the world’s leading artificial intelligence companies all warn of risks from their own creations, it…”, “datePublished”: “2026-07-18T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “Muhammad Asim”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.2bme.xyz/”}, “citation”: [{“@type”: “CreativeWork”, “url”: “https://en.wikipedia.org/wiki/Sam_Altman”}]}
